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Abstract The authors describe a 9 month old female with
recurrent atypical central neurocytoma and leptomeningeal
spread treated with high dose chemotherapy, autologous
stem cell rescue, and adjuvant therapy. She had a complete
response to therapy and was disease free at 4 years of age
until a recurrence 6 months later. The use of intensive
chemotherapy followed by autologous stem cell rescue for
atypical neurocytoma may be considered as an adjunct to
surgical therapy in young patients with atypical neurocy-
toma not amenable to radiation therapy.
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Introduction
Atypical central neurocytomas are rare central nervous
system tumors in the pediatric population [1, 2]. They are
treated unsuccessfully with gross total resection and require
consolidative radiation therapy or chemotherapy to prevent
recurrence [3–5]. The atypical nature and aggressive
behavior of the central neurocytoma we describe in our
patient along with her young age led to the use of systemic
chemotherapy. The use of chemotherapy in the treatment of
typical and atypical central neurocytoma is reported in adults
and children [6–16]. This is the second report describing the
use of high dose chemotherapy followed by autologous stem
cell rescue in a child with atypical central neurocytoma [17].
Case report
We describe a 14 month old female with episodic agitation
upon awakening followed by a very intense episode of
agitation with associated respiratory compromise. She was
transported to a local hospital where CT imaging demon-
strated a large hemorrhagic lesion in the right frontal lobe
extending into the right lateral ventricle (see Fig. 1a). A
gross total resection of this hemorrhagic lesion was com-
pleted as demonstrated by CT imaging (see Fig. 1b).
Microscopic evaluation showed an atypical neurocytic
tumor (see Fig. 2a–d). The histology was that of a mildly
pleomorphic round cell tumor with diffuse, strong immu-
nolabeling for synaptophysin. The tumor cells were negative
for glial fibrillary acidic protein (GFAP). Atypical features
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were noted including the presence of mitoses, glomeruloid
vascular proliferation, and necrosis. The Ki-67 labeling
index was 10% overall though focally was higher. A
decision to avoid consolidative radiation therapy was made
secondary to her young age.
Two months after her resection she developed a recur-
rence with obstructive hydrocephalus and midline shift
requiring placement of a ventriculo-peritoneal shunt.
Imaging demonstrated diffuse meningeal enhancement as
well as interval development of an area of local enhance-
ment concerning for recurrence (see Fig. 3). Her CSF was
negative for evidence of malignant cells. She subsequently
received 3 cylces of chemotherapy including vincristine
(0.05 mg/kg/dose, Days 1 & 8), cisplatin (3.5 mg/kg/dose,
Day 2), and etoposide (2.5 mg/kg/dose, Days 1–3). This was
followed by GCSF beginning on day 3. Imaging demon-
strated a partial response with decreased leptomeningeal and
local enhancement in the resection cavity. She was then
given 2 cycles of temodar for (Days 1–5).
At 24 months she was noted to have development of a
cystic lesion in the resection cavity and increased leptome-
ningeal enhancement. As a result, she then received 2 cycles
of cytoxan (55 mg/kg/dose, Days 1–2) and MESNA; how-
ever, the second cycle was complicated by hyponatremia and
Fig. 1 a Preoperative post
contrast coronal CT images
demonstrating a hemorrhagic
lesion in the right frontal lobe
extending into the right lateral
ventricle. b Postoperative post
contrast coronal CT images
demonstrating a gross total
resection of the right frontal
lesion
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seizures. She was then placed back on the chemotherapy
regimen consisting of vincristine, cisplatin, and etoposide.
Repeat imaging demonstrated stable disease.
At 28 months of age prior to the completion of additional
chemotherapy she underwent GCSF mobilized peripheral
blood stem cell collection. A total of 12 9 106 CD34? cells/
kg were collected in anticipation of high dose chemotherapy
and autologous stem cell rescue. Additional chemotherapy
was provided with 3 cycles of ifosfamide (1800 mg/m2/dose
Days 1–5), carboplatin (400 mg/m2/dose Days 1–2), and
etoposide (100 mg/m2/dose Days 1–5). Repeat imaging was
completed demonstrating stable disease.
Due to a lack of significant clinical response and
nephrotoxicity (hypomagnesaemia, hypokalemia, and aca-
demia) she was then treated with cytoxan and topotecan per
Pediatric Oncology Group Protocol 9464. She received one
cycle of therapy followed by imaging demonstrating
interval progression of her leptomeningeal disease.
At 34 months of age, high dose chemotherapy per the
consolidation phase of Children’s Cancer Group Protocol
99703 was started. This chemotherapy regimen consisted
of carboplatin (17 mg/kg, Days 0–1) and thiotepa (10 mg/
kg, Days 0–1). This was followed by a day of rest, stem
cell infusion, and then GCSF. This phase was repeated
Fig. 1 continued
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every 4 weeks for 3 cycles with the infusion of 2.4 9 106
CD34? cells/kg, 3.68 9 106 CD34? cells/kg, and 3.86 9
106 CD34? cells/kg, respectively. Toxicity included fever
and neutropenia.
At 40 months of age she was disease free by imaging
criteria and was started on isotretinoin (8 mg/kg/day,
14 days/month) and oral etoposide (3 mg/kg/day, 21 days/
month) for 8 months until the development of neutropenia.
Unfortunately, 6 months later abnormal enhancement in
the cervical, thoracic, or lumbar spine was noted on MRI,
suggesting recurrent disease (see Fig. 4). Surgical biopsy
confirmed the diagnosis. Following her most recent relapse,
a decision was made to begin therapy with temodar (5 days
per week every 2 weeks) and irinotecan (every 2 weeks).
She is tolerating this therapy without complications and is
currently waiting for re-imaging.
Discussion
Central neurocytoma, first described in 1982, is a rare
central nervous system (CNS) tumor that accounts for
0.1–0.5% of CNS tumors [1, 2]. This tumor typically
affects young adults in their third decade of life [1, 2].
Neurocytomas are believed to arise from subependymal
plate of lateral ventricles and are believed to be neuronal or
Fig. 3 Post contrast coronal
and axial T1-weighted images
show nodular enhancement
(black arrow) along the margin
of the right posterior frontal
resection cavity, suggesting
recurrent tumor
Fig. 2 a Microscopic
evaluation showed an atypical
neurocytic tumor composed of
cells with round to oval nuclei.








d The Ki-67 labeling index was
approximately 10% overall
(4009)
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neuroglial in origin [1, 2]. Histologically they are divided
into typical and atypical central neurocytomas [1, 2].
Microscopically they appear as small round cells with
round nuclei and scant cytoplasm and will often stain
positive for synaptophisin. Typical central neurocytomas
are well differentiated and benign appearing; however,
atypical central neurocytomas are less well differentiated
and malignant appearing. The presence of necrosis, increased
mitotic activity, and vascular proliferation is not uncom-
mon. Clinically they also behave aggressively.
Treatment of atypical central neurocytoma in children
relies upon surgical therapy and radiation therapy [3–5].
Rades and colleagues provided a retrospective review 438
cases of central neurocytoma [5]. Of these 438 cases 73
patients were 18 years of younger at the time of initial
surgery. The median age of the sample was 16 years.
Typical central neurocytomas comprised 62 individuals in
the sample and atypical central neurocytomas only 11
individuals. A median follow up of 36 months was pro-
vided. Those individuals that had a complete resection
with or without radiation therapy had an excellent 5 year
overall survival rate. Those individuals that had an incom-
plete resection followed by radiation therapy achieved
improved local control rates, but did not benefit from
improved overall survival. This data suggests that durable
cures are likely in individuals that achieve a complete
resection; however, this data did not parse out responses of
atypical central neurocytomas from typical neurocytomas.
Based upon the extant literature present in Table 1, there
is little experience with the use of conventional chemo-
therapy for atypical central neurocytoma and high dose
chemotherapy followed by autologous stem cell transplant
for atypical central neurocytoma [6–17]. Our patient was
disease free by imaging criteria following the completion of
high dose chemotherapy and autologous stem cell rescue
which is a notable difference when looking at the cases
described previously; however, the duration of this remis-
sion was brief. Myeloablative chemotherapy followed by
autologous stem cell rescue has been reported as an effec-
tive consolidative therapy for patients with malignant brain
tumors and those individuals that are not candidates for
radiation therapy [18–21]. Avoidance or delay of radiation
therapy use may also help limit some of the potential long-
term complications of craniospinal irradiation including
increased risk of future second cancers, neuro-cognitive
dysfunction, and endocrinologic deficits [22–24].
Moreover, the use of novel therapeutic agents should be
considered in these patients as we described above. As an
Fig. 4 Post contrast sagittal T1
and axial T1-weighted images
show enhancement of the
surface of the cord (white
arrow), suggesting recurrent
disease
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example, the use of retinoids in the care of children with
brain tumors is under investigation [25, 26]. Their potent
anti-tumor effect which occurs by induction of neuronal
differentiation, growth arrest, and apoptosis has been
demonstrated in childhood cancers with neuronal differ-
entiation such as neuroblastoma [27]. Isotretinoin and other
novel retinoids are currently under investigation as thera-
peutic adjuncts in a host of childhood cancers including
brain tumors. Another novel modality used for this patient
was low-dose continuous chemotherapy or ‘‘metronomic’’
therapy with oral etoposide. Several recent articles have
successfully utilized metronomic combinations of agents
such as oral etoposide, isotretinoin, thalidomide, cyclo-
phosphamide, and celecoxib in children and adults with
brain tumors [28, 29]. The mechanism of metronomic
therapy is believed to be due in part to anti-angiogenic
effects although further research is needed to fully under-
stand the complete biology of this approach. A recent
publication described the use of metronomic therapy for
ten pediatric patients under 5 years old with malignant
brain tumors following high-dose chemotherapy and
autologous stem cell rescue [30]. Similar to our case, it was
tolerated well and had encouraging activity suggesting that
this approach may warrant further evaluation in larger
clinical trials.
Conclusion
Atypical central neurocytoma is a rare central nervous
system tumor in children. Surgical resection and radiation
therapy serves as the mainstay of therapy for atypical cen-
tral neurocytoma. The toxicity of radiation therapy in young
children poses a risk to the use of this therapy in the treat-
ment of atypical central neurocytomas including examples
such as neuro-cognitive deficits and second cancers. Those
young patients with atypical neurocytomas that behave
aggressively may also be candidates for the use of systemic
chemotherapy. Limited experience with the use of chemo-
therapy and myeloablative chemotherapy followed by
autologous stem cell rescue in central neurocytoma is
described. We add to the literature a case describing the use
of intensive chemotherapy followed by autologous stem
cell rescue. Further exploration of this potentially effective
modality of therapy in combination with other novel
adjunctive therapeutic agents and approaches is needed in
patients with atypical central neurocytoma that is refractory
to traditional curative therapy.
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